Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
The Potential Benefit for a Blood-Based Test to Detect a T790M Mutation
September 9th 2014Paul A. Bunn, Jr., MD, Giant of Cancer Care: Lung Cancer, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the potential benefit for a blood-based test to detect a T790M mutation in lung cancer.
Watch
T-VEC in Combination with Ipilmumab for Melanoma Treatment
August 30th 2014Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma
Watch
Toxicity Profile of Panobinostat as seen in the PANORAMA Trial
August 22nd 2014Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Watch
Endocrine Resistance Therapy in Early-Stage Breast Cancer
August 21st 2014Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses the possibility of using endocrine resistance therapy to treat patients with early stage breast cancer.
Watch
Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma
August 21st 2014Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma. The data presented at the 2014 ASCO Annual Meeting was an updated survival and clinical activity analysis in initially enrolled cohorts and activity by BRAF mutation status.
Watch
Improving the Cure Rate and the Burden of Cure in Prostate Cancer
August 15th 2014Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Watch
Current TKI Therapy Practices and TKI Combinations in Lung Cancer
August 8th 2014James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses current practices for administering TKI therapy and the potential for TKI combinations.
Watch
Challenges in the Field of Hereditary Breast Cancer
August 8th 2014Claudine Isaacs, MD, professor, medical Director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses some of the challenges physicians are facing in the field of hereditary breast cancer.
Watch
An Analysis of the Phase III ATLAS Trial in RCC​
August 6th 2014Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Watch
Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial
August 5th 2014Edith A. Perez, MD, Breast Cancer: Giant of Cancer Care; deputy director at large, Mayo Clinic Cancer Center, Serene M. and Frances C. Durling professor of Medicine, Division of Hematology/Oncology, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Watch